OMB No. 3117-0016/USITC No. 05-1-2273; Expiration Date: 6/30/05
(No response is required if currently valid OMB control number is not displayed)

PRODUCERS' QUESTIONNAIRE

POLYCHLOROPRENE RUBBER FROM JAPAN

Return completed questionnaire to:

UNITED STATES INTERNATIONAL TRADE COMMISSION
Office of Investigations, Room 615
500 E Street, SW, Washington, DC 20436

So as to be received by the Commission by no later than March 3, 2005

The information called for in this questionnaire is for use by the United States International Trade Commission in connection with its antidumping review investigation concerning polychloroprene rubber (PCR) from Japan (inv. No. AA1921-129 (Second Review)). The information requested in the questionnaire is requested under the authority of the Tariff Act of 1930, title VII. This report is mandatory and failure to reply as directed can result in a subpoena or other order to compel the submission of records or information in your possession (19 U.S.C. § 1333(a)).

Name of firm _____

Address _____

City _____ **State** _____ **Zip code** _____

World Wide Web address _____

Has your firm produced PCR (as defined in the instruction booklet) at any time since January 1, 1999?

☐ **NO** (Sign the certification below and promptly return only this page of the questionnaire to the Commission)

☐ **YES** (Read the instruction booklet carefully, complete all parts of the questionnaire, sign the certification, and return the entire questionnaire to the Commission)

CERTIFICATION

I certify that the information herein supplied in response to this questionnaire is complete and correct to the best of my knowledge and belief and understand that the information submitted is subject to audit and verification by the Commission.

By signing this certification I also grant consent for the Commission, and its employees and contract personnel, to use the information provided in this questionnaire and throughout this review in any other import-injury investigations or reviews conducted by the Commission on the same or similar merchandise. (If you do not consent to such use, please note the certification accordingly.)

I acknowledge that information submitted in this questionnaire response and throughout this review may be used by the Commission, its employees, and contract personnel who are acting in the capacity of Commission employees, for developing or maintaining the records of this review or related proceedings for which this information is submitted, or in internal audits and investigations relating to the programs and operations of the Commission pursuant to 5 U.S.C. Appendix 3. I understand that all contract personnel will sign non-disclosure agreements.

_____ _____
Name and Title of Authorized Official ***Date***

_____ ***(___)*** _____ ***(___)*** _____
Signature of Authorized Official ***Phone*** ***Fax***

PART I.--GENERAL QUESTIONS

The questions in this questionnaire have been reviewed with market participants to ensure that issues of concern are adequately addressed and that data requests are sufficient, meaningful, and as limited as possible. Public reporting burden for this questionnaire is estimated to average 40 hours per response, including the time for reviewing instructions, searching existing data sources, gathering the data needed, and completing and reviewing the questionnaire. Send comments regarding the accuracy of this burden estimate or any other aspect of this collection of information, including suggestions for reducing the burden, to the Office of Investigations, U.S. International Trade Commission, 500 E Street, SW, Washington, DC 20436.

I-1a. Please report below the actual number of hours required and the cost to your firm of preparing the reply to this questionnaire and completing the form.

_____ hours _____ dollars

I-1b. We are interested in any comments you may have for improving this questionnaire in general or the clarity of specific questions. Please attach such comments to your response or send them to the above address.

I-2. Provide the name and address of establishment(s) covered by this questionnaire (see pages 3-4 of the instruction booklet for reporting guidelines). If your firm is publicly traded, please specify the stock exchange and trading symbol.

_____

_____

_____

I-3. Do you support or oppose continuation of the antidumping finding currently in place for PCR from Japan? Please explain.

☐ Support ☐ Oppose ☐ Take no position

_____

_____

I-4. Is your firm owned, in whole or in part, by any other firm?

☐ No ☐ Yes--List the following information.

Firm name	Address	Extent of ownership

PART I.--GENERAL QUESTIONS--*Continued*

I-5. Does your firm have any related firms, either domestic or foreign, which are engaged in importing PCR from Japan into the United States or which are engaged in exporting PCR from Japan to the United States?

☐ No ☐ Yes--List the following information.

Firm name	Address	Affiliation

I-6. Does your firm have any related firms, either domestic or foreign, which are engaged in importing PCR from countries other than Japan into the United States or which are engaged in exporting PCR from countries other than Japan to the United States?

☐ No ☐ Yes--List the following information.

Country/firm name	Address	Affiliation

I-7. Does your firm have any related firms, either domestic or foreign, which are engaged in the production of PCR?

☐ No ☐ Yes--List the following information.

Firm name	Address	Affiliation

I-8. In Parts II and IV of this questionnaire we request a copy of your company's most recent business plans. Does your company or any related firm have a business plan or any internal documents that describe, discuss, or analyze expected future market conditions for PCR?

☐ No ☐ Yes--Please provide the requested documents. If you are not providing the requested documents, please explain why not.

_____

_____

_____

PART II.--TRADE AND RELATED INFORMATION

Further information on this part of the questionnaire can be obtained from John Kitzmiller (202-205-3387). **Supply all data requested on a calendar-year basis.**

II-1. Who should be contacted regarding the requested trade and related information?

Company contact: _____
Name and title

_____ _____
Phone No. E-mail address

II-2. Has your firm experienced any plant openings, relocations, expansions, acquisitions, consolidations, closures, or prolonged shutdowns because of strikes or equipment failure; curtailment of production because of shortages of materials; or any other change in the character of your operations or organization relating to the production of PCR since December 6, 1973 (the date on which the antidumping finding under review became effective)?

☐ No ☐ Yes--Supply details as to the time, nature, and significance of such changes.

_____

_____

II-3. Does your firm anticipate any changes in the character of your operations or organization (as noted above) relating to the production of PCR in the future?

☐ No ☐ Yes--Supply details as to the time, nature, and significance of such changes and provide underlying assumptions, along with relevant portions of business plans or other supporting documentation, that address this issue. **Include in your response a specific projection of your firm's capacity to produce PCR (in 1,000 pounds) for 2005 and 2006.**

_____

_____

II-4. Would your firm anticipate any changes in the character of your operations or organization (as noted above) relating to the production of PCR in the future if the antidumping finding on PCR from Japan were to be revoked?

☐ No ☐ Yes--Supply details as to the time, nature, and significance of such changes and provide underlying assumptions, along with relevant portions of business plans or other supporting documentation, that address this issue.

_____

_____

_____

PART II.--TRADE AND RELATED INFORMATION--*Continued*

II-5. Has your firm since December 6, 1973 (the date the antidumping finding under review became effective) produced, or does your firm anticipate producing in the future, other products on the same equipment and machinery used in the production of PCR and/or using the same production and related workers employed to produce PCR?

☐ No ☐ Yes--List the following information and report your firm's combined production capacity and production of these products and PCR in the periods indicated.

Product	Period	Basis for allocation of capacity and employment data (indicate if different)

(*Quantity* in 1,000 pounds)						
Item	**1999**	**2000**	**2001**	**2002**	**2003**	**2004**
AVERAGE PRODUCTION CAPACITY						
PRODUCTION						

II-6. Please describe the constraint(s) that set the limit(s) on your production capacity.

II-7. Is your firm able to switch production between PCR and other products in response to a relative change in the price of PCR vis-a-vis the price of other products, using the same equipment and labor?

☐ No ☐ Yes--Please identify the other products, the approximate time and cost involved in switching, and the minimum relative price change required for your firm to switch production to or from PCR.

PART II.--TRADE AND RELATED INFORMATION--*Continued*

II-8. Report your firm's production capacity, production, shipments, inventories, and employment related to the production of PCR in your U.S. establishment(s) during the specified periods. (See definitions in the instruction booklet.)

(*Quantity* in 1,000 pounds, *value* in $1,000)						
Item	**1999**	**2000**	**2001**	**2002**	**2003**	**2004**
AVERAGE PRODUCTION CAPACITY[1] (*quantity*)						
BEGINNING-OF-PERIOD INVENTORIES (*quantity*)						
PRODUCTION (*quantity*)						
U.S. SHIPMENTS:						
Commercial shipments:						
Quantity of commercial shipments						
Value of commercial shipments						
Internal consumption:						
Quantity of internal consumption						
Value[2] of internal consumption						
Transfers to related firms:						
Quantity of transfers to related firms						
Value[2] of transfers to related firms						
EXPORT SHIPMENTS:[3]						
Quantity of export shipments						
Value of export shipments						
END-OF-PERIOD INVENTORIES[4] (*quantity*)						
U.S. SHIPMENTS TO DISTRIBUTORS (*quantity*)						
U.S. SHIPMENTS TO END USERS (*quantity*)						
AVERAGE NUMBER OF PRWs						
HOURS WORKED BY PRWs (*1,000 hours*)						
WAGES PAID TO PRWs (*value*)						

[1] The production capacity (see definitions in instruction booklet) reported is based on operating _____ hours per week, _____ weeks per year. Please describe the methodology used to calculate production capacity, and explain any changes in reported capacity (use additional pages as necessary).

_____

_____

[2] Internal consumption and transfers to related firms must be valued at fair market value. In the event that you use a different basis for valuing these transactions, please specify that basis (e.g., cost, cost plus, etc.) and provide value data using that basis for 1999-2004 below:

_____

_____

[3] Identify your principal export markets: _____.

[4] Reconciliation of data.--Please note that the **quantities** reported above should reconcile as follows: beginning-of-period inventories, plus production, less total shipments, equals end-of-period inventories. Do the data reported reconcile?

☐ Yes ☐ No--Please explain: _____.

PART II.--TRADE AND RELATED INFORMATION--*Continued*

II-9. If you reported transfers to related firms in question II-8, please indicate the nature of the relationship between your firm and the related firms (e.g., joint venture, wholly owned subsidiary), whether the transfers were priced at market value or by a non-market formula, whether your firm retained marketing rights to all transfers, and whether the related firms also processed inputs from sources other than your firm.

II-10. Report your firm's total U.S. shipments of PCR for the specified end uses. Totals should conform to the sum of U.S. commercial shipments, U.S. internal consumption, and U.S. transfers to related firms reported in response to question II-8.

(*Quantity* in 1,000 pounds)						
Item	**1999**	**2000**	**2001**	**2002**	**2003**	**2004**
Adhesives and sealants						
Belts and hoses						
Latex or dipped goods						
Wire and cable						
Other						
Unknown						
Total						

PART II.--TRADE AND RELATED INFORMATION--*Continued*

II-11. Other than direct imports, has your firm otherwise purchased PCR since January 1, 1999? (See definitions in the instruction booklet.)

☐ No

☐ Yes--Report such purchases below for the specified periods.[1]

(*Quantity* in 1,000 pounds, *value* in $1,000)						
Item	**1999**	**2000**	**2001**	**2002**	**2003**	**2004**
PURCHASES FROM U.S. IMPORTERS[2] OF PCR FROM--						
JAPAN:						
Quantity						
Value						
ALL OTHER COUNTRIES:						
Quantity						
Value						
PURCHASES FROM DOMESTIC PRODUCERS:[2]						
Quantity						
Value						
PURCHASES FROM OTHER SOURCES:[2]						
Quantity						
Value						

[1] Please indicate your reasons for purchasing this product. If your reasons differ by source, please elaborate.

[2] Please list the name of the firm(s) from which you purchased this product. If your suppliers differ by source, please identify the source for each listed supplier.

PART II.--TRADE AND RELATED INFORMATION--*Continued*

II-12. Since January 1, 1999, has your firm been involved in a toll agreement (see definition in the instruction booklet) regarding the production of PCR?

☐ No ☐ Yes--Name firm(s): _____

II-13. Does your firm produce PCR in a foreign trade zone (FTZ)?

☐ No ☐ Yes--Identify FTZ(s): _____

II-14. Since January 1, 1999, has your firm imported PCR?

☐ No ☐ Yes--***COMPLETE AND RETURN THE ENCLOSED IMPORTERS' QUESTIONNAIRE***

II-15. Describe the significance of the existing antidumping finding covering imports of PCR from Japan in terms of its effect on your firm's production capacity, production, U.S. shipments, inventories, purchases, employment, revenues, costs, profits, cash flow, capital expenditures, research and development expenditures, and asset values. You may wish to compare your firm's operations before and after the finding.

_____

_____

_____

_____

II-16. Would your firm anticipate any changes in its production capacity, production, U.S. shipments, inventories, purchases, employment, revenues, costs, profits, cash flow, capital expenditures, research and development expenditures, or asset values relating to the production of PCR in the future if the antidumping finding on PCR from Japan were to be revoked?

☐ No ☐ Yes--Supply details as to the time, nature, and significance of such changes and provide underlying assumptions, along with relevant portions of business plans or other supporting documentation, for any trends or projections you may provide.

_____

_____

_____

_____

PART III.--FINANCIAL INFORMATION

Address questions on this part of the questionnaire to Charles Yost (202-205-3432 or charles.yost@usitc.gov).

III-1. Identify the individual who prepared or has knowledge of the requested financial information.

Company contact: _____
Name and title

_____ _____
Phone No. Fax No.

_____ _____
E-mail address Company web address

III-2. Briefly describe your financial accounting system.

A. When does your fiscal year end (month and day)? _____
If your fiscal year changed during the period examined, explain below:

_____

B.1. Describe the lowest level of operations (e.g., plant, division, company-wide) for which financial statements are prepared that include subject merchandise: _____

2. Does your firm prepare profit/loss statements for the subject merchandise? Yes___No____
3. How often did your firm (or parent company) prepare financial statements (including annual reports, 10Ks)? Please check relevant items below.
   Audited ____ unaudited ____ annual reports ____ 10Ks ____ 10Qs ____
   Monthly ____ quarterly ____ semi-annually ____ annually ____
4. Accounting basis: GAAP ____ cash ____ tax ____ other comprehensive (specify) _____

Note: Please submit and attach copies of its financial statements, including internal profit-and-loss statements for the division or product group that includes PCR, as well as those statements and worksheets used to compile data for your firm's questionnaire response.

III-3. Briefly describe your cost accounting system (e.g., standard cost, job order cost, etc.).

_____
_____
_____

III-4. Briefly describe your allocation basis, if any, for COGS, SG&A, and interest expense and other income and expenses.

_____
_____
_____

PART III.--FINANCIAL INFORMATION--*Continued*

III-5. Other products.--Please list any other products you produced in the facilities in which you produced PCR, and provide the share of net sales accounted for by these other products in your most recent fiscal year:

Product(s)	**Share of sales**

III-6. If your firm receives inputs (raw materials, labor, energy, or any other services) used in the production of PCR from any related companies, describe the nature of the affiliation and the extent of control these related firms have on your firm and the extent of control your firm has on these related firms.

III-7. When your firm's financial statements are prepared, are they consolidated with the financial statements of any of the related companies in question III-6 above? (In other words, are any profits or losses arising from intercompany transactions eliminated?)

☐ No ☐ Yes–Complete question III-8 below.

III-8. Identify the inputs by period, 1999-2004, if any, your firm receives from related parties whose financial statements are consolidated with the financial statements of your firm, in the production of PCR. For each input item, provide the name of the related party and the basis for the transfer price (i.e., cost, cost plus, market). Reasonable estimates are acceptable.

Input	Related Party	Transfer Price Basis

PART III.--FINANCIAL INFORMATION--*Continued*

III-9. Operations on PCR.--Report the revenue and related cost information requested below on the total PCR (include all types of PCR) operations of your U.S. establishment(s).[1] Do not report resales of product. Note that internal consumption and transfers to related firms must be valued at fair market value and purchases from related firms must be at cost. Provide data for your six most recently completed fiscal years in chronological order from left to right. If your firm was involved in tolling operations (either as the toller or as the tollee) please contact Charles Yost at (202) 205-3432 before completing this section of the questionnaire.

(*Quantity* in 1,000 pounds, *value* in $1,000)						
Item	**1999**	**2000**	**2001**	**2002**	**2003**	**2004**
Net sales quantities:[2]						
Commercial sales						
Internal consumption						
Transfers to related firms						
Total net sales quantities						
Net sales values:[2]						
Commercial sales						
Internal consumption						
Transfers to related firms						
Total net sales values						
Cost of goods sold (including internal consumption and transfers to related firms):						
Raw materials						
Direct labor						
Other factory costs						
Total cost of goods sold						
Gross profit or (loss)						
Selling, general, and administrative (SG&A) expenses:						
Selling expenses						
General and administrative expenses						
Total SG&A expenses						
Operating income or (loss)						
Other income and expenses:						
Interest expense						
All other expense items						
Continued Dumping and Subsidy Offset Act funds received[3]						
All other income items						
All other income or expenses, net						
Net income or (loss) before income taxes						
Depreciation/amortization included above						

[1] Include only sales (whether domestic or export) and costs related to your U.S. manufacturing operations.

[2] Less discounts, returns, allowances, and prepaid freight. The quantities and values should approximate the corresponding shipment quantities and values reported in Part II of this questionnaire.

[3] Please report funds received under this act (and associated time periods). Do not report these funds as an offset to operating expenses.

PART III.--FINANCIAL INFORMATION--*Continued*

III-10. Identify and list the corporate expenses allocated to PCR in question III-9 and state where they are classified in III-9. Provide data for the specified calendar years. Use a separate page if necessary.

(Value in $1,000)						
Item	**1999**	**2000**	**2001**	**2002**	**2003**	**2004**

III-11. If your firm has included any funds in your operations on PCR in question III-9 that are in settlement of litigation, reserves set aside for damages and penalties, and other legal or associated costs related to price-fixing or other anticompetitive arrangements, please state the amounts, where those amounts are classified, and the parties to whom the amounts were paid. Provide data for the specified calendar years. Use a separate page if necessary.

(Value in $1,000)						
Item (where classified)	**1999**	**2000**	**2001**	**2002**	**2003**	**2004**

PART III.--FINANCIAL INFORMATION–Continued

III-12. Asset values.--Report the total assets associated with the production, warehousing, and sale of PCR. If your firm does not maintain some or all of the specific asset data in the normal course of business, please estimate it based upon some rational method (such as production, sales, or costs) that is consistent with your cost allocations in the previous question. Your finished goods inventory value should reconcile with the inventory quantity data reported in Part II. Provide data as of the end of the specified calendar years in chronological order from left to right.

(*Value* in $1,000)						
Value of	**1999**	**2000**	**2001**	**2002**	**2003**	**2004**
Assets associated with the production, warehousing, and sale of product:						
1. Current assets:						
A. Cash and equivalents						
B. Accounts receivable, net						
C. Inventories (finished goods)						
D. Inventories (raw materials and work in process)						
E. Short-term investments						
F. Prepaid expenses						
G. Property held for resale						
H. Other (describe_____)						
I. Total current assets (lines 1.A. through 1.H.)						
2. Notes receivable						
3. Long-term investments						
4. Property, plant, and equipment						
A. Original cost of property, plant, and equipment						
B. Less: Accumulated depreciation						
C. Equals: Book value of property, plant, and equipment						
5. Goodwill						
6. Other (describe_____)						
7. Other (describe_____)						
8. Total assets (lines 1.I., 2, 3, 4.C., 5, 6, and 7)						

III-13. Capital expenditures and research and development expenditures.--Report your firm's capital expenditures and research and development expenditures on PCR. Provide data for the specified calendar years in chronological order from left to right.

(*Value* in $1,000)						
Item	**1999**	**2000**	**2001**	**2002**	**2003**	**2004**
Capital expenditures						
Research and development expenditures						

PART IV.--PRICING AND MARKET FACTORS

Further information on this part of the questionnaire can be obtained from Robert Hughes (202-205-3300).

IV-1. Who should be contacted regarding the requested pricing and related information?

Company contact: _____
Name and title

_____ _____
Phone No. E-mail address

Section IV-A.--PRICE DATA

This section requests quarterly quantity and value data on your firm's U.S. shipments of the following products during January 1999-December 2004. Values should be for arms-length sales to unrelated U.S. customers, f.o.b. U.S. point of shipment, net of returns, refunds, discounts, and credits.

***Product 1*.–PCR for industrial goods; a sulfur-modified type with Mooney viscosity 36 to 55, equivalent to DuPont Dow type GRT or Denka type PS40, in solid "chips."**

***Product 2*.--PCR for industrial goods, with low temperature resistance, high crystallization resistance, Mooney viscosity 43 to 53, equivalent to DuPont Dow type WRT or Denka type S-40V, in solid "chips."**

***Product 3*.--PCR for general purpose solvent-based adhesives, equivalent to DuPont Dow type AD or Denka type A.**

***Product 4*.--PCR equivalent to DuPont Dow type SND35 or Denka type DCR35, in solid "chips."**

COPY THE FOLLOWING PAGE AS NECESSARY. Complete a separate page for each of the specified products produced and sold by your firm. Indicate in the space provided at the top of the page the product for which pricing is reported.

PART IV.--PRICING AND MARKET FACTORS--*Continued*

Section IV-A.--PRICE DATA--*Continued*

☐ **Product 1** ☐ **Product 2** ☐ **Product 3** ☐ **Product 4**

(*Quantity* in pounds, *value* in dollars)		
Period of shipment	**Quantity**	**Value[1]**
1999:		
January-March		
April-June		
July-September		
October-December		
2000:		
January-March		
April-June		
July-September		
October-December		
2001:		
January-March		
April-June		
July-September		
October-December		
2002:		
January-March		
April-June		
July-September		
October-December		
2003:		
January-March		
April-June		
July-September		
October-December		
2004:		
January-March		
April-June		
July-September		
October-December		

[1] Net values (i.e., gross sales values less all discounts, allowances, rebates, prepaid freight, and the value of returned goods), f.o.b. your U.S. point of shipment.

Note.--If your product does not exactly meet the product specifications but is competitive with the specified product, provide a description of your product:

_____

PART IV.--PRICING AND MARKET FACTORS--*Continued*

Section IV-B.--PRICE-RELATED QUESTIONS

Please note that the questions in this section refer to the entire period since 1973, unless otherwise specified. If your response to any question differs for different time periods since 1973, please note this in your response (identifying the month/year to which your are referring).

IV-B-1. Please describe how your firm determines the prices that it charges for sales of PCR (transaction by transaction negotiation, contracts for multiple shipments, set price lists, etc.). If your firm issues price lists, please include a copy of a recent price list with your submission. If your price list is large, please submit sample pages.

IV-B-2. Please describe your firm's discount policy (quantity discounts, annual total volume discounts, etc.).

IV-B-3. What are your firm's typical sales terms for its U.S.-produced PCR (e.g., 2/10 net 30 days)? _____ On what basis are your prices of domestic PCR usually quoted (e.g., f.o.b. warehouse, or delivered)? _____

IV-B-4. Approximately what share of your firm's sales of its U.S.-produced PCR in 2004 were on a (1) long-term contract basis (multiple deliveries for more than 12 months), (2) short-term contract basis (multiple deliveries up to 12 months), and (3) spot sales basis (for a single delivery)?

Type of sale	Share of sales (percent)
Long-term contracts	
Short-term contracts	
Spot sales	

IV-B-5. If you sell on a long-term contract basis, please answer the following questions with respect to provisions of a typical long-term contract.

(a) What is the average duration of a contract? _____

(b) Can prices be renegotiated during the contract period? _____

(c) Does the contract fix quantity, price, or both? _____

(d) Does the contract have a meet or release provision? _____

PART IV.--PRICING AND MARKET FACTORS--*Continued*

Section IV-B.--PRICE-RELATED QUESTIONS

IV-B-6. If you sell on a short-term contract basis, please answer the following questions with respect to provisions of a typical short-term contract.

(a) What is the average duration of a contract? _____

(b) Can prices be renegotiated during the contract period? _____

(c) Does the contract fix quantity, price, or both? _____

(d) Does the contract have a meet or release provision? _____

IV-B-7. What is the average lead time between a customer's order and the date of delivery for your firm's sales of your U.S.-produced PCR?

Source	Share of 2004 sales	Lead time
From inventory		
Produced to order		
Total	**100%**	

IV-B-8. (a) What is the approximate percentage of the total delivered cost of PCR that is accounted for by U.S. inland transportation costs? _____ percent.

(b) Who generally arranges the transportation to your customers' locations? Your firm _____ or purchaser _____ (check one).

(c) Approximately what proportion of your sales occur within 100 miles of your storage or production facility? _____ percent. 101 to 1,000 miles? _____ percent. Over 1,000 miles? _____ percent.

IV-B-9. What is the geographic market area in the United States served by your firm's PCR?

☐ Northeast ☐ Mid-Atlantic ☐ Midwest ☐ Southeast

☐ Southwest ☐ Rocky Mountains ☐ West Coast ☐ Northwest

☐ National ☐ Other (describe) _____

Section IV-B.--PRICE-RELATED QUESTIONS--*Continued*

IV-B-10. Describe the end uses of the PCR that you manufacture. For each end-use product, what percentage of the total cost is accounted for by PCR?

End use	Share of total cost accounted for by PCR (percent)

IV-B-11. Have there been any changes in the end uses of PCR since 1973?

☐ No ☐ Yes--Please describe.

IV-B-12. Do you anticipate any changes in terms of the end uses of PCR in the future?

☐ No ☐ Yes--Please describe and identify the time period. Provide any underlying assumptions, along with relevant portions of business plans or other supporting documentation, that address this issue.

IV-B-13. (a) Please list in order of importance any products that may be substituted for PCR.

(1) _____ (2) _____ (3) _____

(b) For each possible substitute product, please give examples of applications and end uses for which they are substitutes.

Section IV-B.--PRICE-RELATED QUESTIONS--*Continued*

IV-B-14. (c) Have changes in the prices of these products affected the price for PCR?

☐ No ☐ Yes–To what degree do changes in their prices affect the price for PCR? Does this effect have a time lag? If so, how long is the time lag for each substitute product? Does this vary by type of PCR or final end use?

IV-B-15. Have there been any changes in the number or types of products that can be substituted for PCR since 1973?

☐ No ☐ Yes--Please explain.

IV-B-16. Do you anticipate any changes in terms of the substitutability of other products for PCR in the future?

☐ No ☐ Yes--Please describe. Provide any underlying assumptions, along with relevant portions of business plans or other supporting documentation, that address this issue.

IV-B-17. To what extent have changes in the prices of raw materials affected your firm's selling prices for PCR during January 1999-December 2004? Also discuss any anticipated changes in your raw material costs in the future, identifying the time period(s) involved and the factor(s) that you believe would be responsible for such changes. Provide any underlying assumptions, along with relevant portions of business plans or other supporting documentation, that address this issue.

PART IV.--PRICING AND MARKET FACTORS--*Continued*

Section IV-B.--PRICE-RELATED QUESTIONS--*Continued*

IV-B-18. Have any changes occurred in any other factors affecting supply (e.g., changes in availability or prices of energy or labor; transportation conditions; production capacity and/or methods of production; technology; export markets; or alternative production opportunities) that affected the availability of U.S.-produced PCR in the U.S. market since 1973?

☐ No ☐ Yes--Please note the time period(s) of any such changes, the factors(s) involved, and the impact such changes had on your shipment volumes and prices.

IV-B-19. (a) Do you anticipate any changes in terms of the availability of U.S.-produced PCR in the U.S. market in the future?

☐ Increase ☐ No Change ☐ Decrease

(b) If you anticipate changes in supply, please identify the changes including the time period and the impact of such changes on shipment volumes and prices. Provide any underlying assumptions, along with relevant portions of business plans or other supporting documentation, that address this issue.

PART IV.--PRICING AND MARKET FACTORS--*Continued*

Section IV-B.--MARKET FACTORS--*Continued*

IV-B-20. Has the availability of NONSUBJECT imported PCR changed since 1973?

☐ No ☐ Yes--Please explain.

IV-B-21. Describe how easily your firm can shift its sales of PCR between the U.S. market and alternative country markets. In your discussion, please describe any contracts, other sales arrangements, or other constraints that would prevent or retard your firm from shifting PCR between the U.S. and alternative country markets within a 12-month period. Provide any underlying assumptions, along with relevant portions of business plans or other supporting documentation, that address this issue.

IV-B-22. Have there been any significant changes in the product range, product mix, or marketing (including sales over the internet) of PCR since 1973?

☐ No ☐ Yes--Please describe and quantify if possible.

IV-B-23. Do you anticipate any changes in terms of the product range, product mix, or marketing (including sales over the internet) of PCR in the future? Provide any underlying assumptions, along with relevant portions of business plans or other supporting documentation, that address this issue.

☐ No ☐ Yes--Please identify, including the time period.

PART IV.--PRICING AND MARKET FACTORS--*Continued*

Section IV-B.--MARKET FACTORS--*Continued*

IV-B-24. How has demand within the United States (and outside the United States, if known) for PCR changed since 1973?

☐ Increased ☐ Unchanged ☐ Decreased

☐ Other (describe) _____

What were the principal factors affecting changes in demand?

_____

_____

IV-B-25. Do you anticipate any future changes in PCR demand in the United States and, if known, the rest of the world?

☐ No ☐ Yes--Please describe and identify the time period. Provide any underlying assumptions, along with relevant portions of business plans or other supporting documentation, that address this issue.

_____

_____

_____

_____

IV-B-26. Please compare market prices of PCR in U.S. and non-U.S. markets, if known. Provide specific information as to time periods and regions for any price comparisons.

_____

_____

_____

_____

PART IV.--PRICING AND MARKET FACTORS--*Continued*

Section IV-B.--MARKET FACTORS--*Continued*

IV-B-27. Please provide as a separate attachment to this request any studies, surveys, etc. that you are aware of that quantify and/or otherwise discuss PCR supply (including production capacity and capacity utilization) and demand in (1) the United States, (2) each of the other major producing/consuming countries, including Japan, and (3) the world as a whole. Of particular interest is such data from 1973 to the present and forecasts for the future.

IV-B-28. Are your exports of PCR subject to any tariff or non-tariff barriers to trade in other countries?

☐ No ☐ Yes--Please list the countries and describe any such barriers and any significant changes in such barriers that have occurred since 1973, or that are expected to occur in the future.

IV-B-29. Does your firm sell PCR over the internet?

☐ No ☐ Yes--Please describe, noting the estimated percentage of your firm's total sales of PCR in 2004 accounted for by internet sales.

PART IV.--PRICING AND MARKET FACTORS--*Continued*

Section IV-B.--PRICE-RELATED QUESTIONS--*Continued*

IV-B-30. Is PCR produced in the United States and in other countries interchangeable (i.e., can they physically be used in the same applications)? Please indicate below, using "A" to indicate that the products from a specified country-pair are *always* interchangeable, "F" to indicate that the products are *frequently* interchangeable,"S" to indicate that the products are *sometimes* interchangeable,"N" to indicate that the products are *never* interchangeable, and "0" to indicate *no familiarity* with products from a specified country-pair.[1]

Country-pair	United States	Japan	Other countries
United States			
Japan			

[1] For any country-pair producing PCR which is *sometimes or never* interchangeable, please explain the factors that limit or preclude interchangeable use:

PART IV.--PRICING AND MARKET FACTORS--*Continued*

Section IV-B.--PRICE-RELATED QUESTIONS--*Continued*

IV-B-31. Are differences other than price (i.e., quality, availability, transportation network, product range, technical support, etc.) between PCR produced in the United States and in other countries a significant factor in your firm's sales of the products? Please indicate below, using "A" to indicate that such differences are *always* significant, "F" to indicate that such differences are *frequently* significant,"S" to indicate that such differences are *sometimes* significant,"N" to indicate that such differences are *never* significant, and "0" to indicate *no familiarity* with products from a specified country-pair.[1]

Country-pair	United States	Japan	Other countries
United States			
Japan			

[1] For any country-pair for which factors other than price *always or frequently* are a significant factor in your firm's sales of PCR, identify the country-pair and report the advantages or disadvantages imparted by such factors: